Mutlu Hayran
Impact in
-
- Cardiovascular Disease and Adiposity
- Chemotherapy-induced cardiotoxicity and mitigation
Papers in
-
- Bacterial Identification and Susceptibility Testing 4
- Co-authors
- Ömrüm UzunHalis AkalınSerhat ÜnalLeyla Elif SadeSüleyman ÖzbiçerHaldun MüderrisoğluHüseyin BozbaşSerpil Eroğlu
- Journals
- Clinical Infectious Diseases (2 papers)Annals of Oncology (2 papers)International Journal of Antimicrobial Agents (2 papers)Journal of Chemotherapy (2 papers)Journal of Clinical Oncology (2 papers)
- Partner nations
- TürkiyeUnited StatesCambodia
In The Last Decade
Mutlu Hayran
62 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 117
- Applied Microbiology and Biotechnology 22
- Cardiology and Cardiovascular Medicine 246
- Clinical Biochemistry 72
- Infectious Diseases 172
- Epidemiology 278
Countries citing papers authored by Mutlu Hayran
This map shows the geographic impact of Mutlu Hayran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mutlu Hayran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mutlu Hayran more than expected).
Fields of papers citing papers by Mutlu Hayran
This network shows the impact of papers produced by Mutlu Hayran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mutlu Hayran. The network helps show where Mutlu Hayran may publish in the future.
Co-authors
The 25 scholars most cited alongside Mutlu Hayran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 1 | |
| 2 | 2017 | 22 | |
| 3 | 2016 | 2 | |
| 4 | 2016 | 2 | |
| 5 | 2016 | 43 | |
| 6 | Hepatoprotective effect of pioglitazone in cases of chemotherapy induced steatohepatitis. | 2015 | 4 |
| 7 | 2014 | 3 | |
| 8 | 2014 | 3 | |
| 9 | 2011 | 35 | |
| 10 | 2010 | 15 | |
| 11 | 2009 | 90 | |
| 12 | 2008 | 13 | |
| 13 | 2008 | 20 | |
| 14 | 2006 | 52 | |
| 15 | 2001 | 33 | |
| 16 | 2000 | 8 | |
| 17 | 1999 | 4 | |
| 18 | 1997 | 10 | |
| 19 | 1994 | 27 | |
| 20 | 1992 | 2 |
About Mutlu Hayran
Mutlu Hayran is a scholar working on Research and Theory, Clinical Biochemistry, General Dentistry, Surgery and Applied Microbiology and Biotechnology, having authored 64 papers that have together received 1.1k indexed citations. Recurring topics across this work include Nerve Injury and Rehabilitation (4 papers), Orthopedic Surgery and Rehabilitation (4 papers), Bacterial Identification and Susceptibility Testing (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Liver Disease Diagnosis and Treatment (3 papers), Antimicrobial Resistance in Staphylococcus (3 papers), Neutropenia and Cancer Infections (3 papers) and Facial Nerve Paralysis Treatment and Research (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (22 citations), Cardiology and Cardiovascular Medicine (246 citations), Clinical Biochemistry (72 citations), Infectious Diseases (172 citations) and Epidemiology (278 citations). Mutlu Hayran has collaborated with scholars based in Türkiye, United States and Cambodia. Frequent co-authors include Ömrüm Uzun, Halis Akalın, Serhat Ünal, Leyla Elif Sade, Süleyman Özbiçer, Haldun Müderrisoğlu, Hüseyin Bozbaş, Serpil Eroğlu, Sesın Kocagöz and Henry F. Chambers. Their work appears in journals such as Clinical Infectious Diseases, Annals of Oncology, International Journal of Antimicrobial Agents, Journal of Chemotherapy and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.